Journal of Clinical Oncology

Early-onset CRC germline genetic differences identified by race, ethnicity

A Vanderbilt study that delved into genetic predisposition for early-onset colorectal cancer by race and ethnicity has identified differing germline risk variants.

Study finds Mark Cuban’s Cost Plus Drug Company could save taxpayers millions on Medicare generic oncology drugs

Vanderbilt research finds that the U.S. government could save taxpayers between $228 million-$2.15 billion a year if insurers who operate its Medicare Part D plans purchased seven generic oncology drugs at the same prices obtained by the Mark Cuban Cost Plus Drug Company.

Study shows better option for treatment of inoperable anal cancer

People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered.

Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy

More than half of patients with relapsed multiple myeloma treated with carfilzomib experienced cardiac issues during treatment, according to a multi-institutional study published June 12 in the Journal of Clinical Oncology.

Report identifies IT upgrades needed to enhance cancer care

A group of nationally recognized medical information and data management experts has recommended the development of new knowledge software applications that work alongside electronic health record systems (EHRs) to help practicing oncologists access and use the latest genomic information to assist in the treatment of cancer patients.

Study finds high soy diet before lung cancer diagnosis improves survival

A new study by researchers at Vanderbilt University Medical Center and the Shanghai Cancer Institute found women who ate more soy food prior to a diagnosis of lung cancer lived longer than those who consumed less. The study, conducted in Shanghai, China, was published in the March 25 issue of the Journal of Clinical Oncology.